Literature DB >> 26703501

Flap lift and photorefractive keratectomy enhancements after primary laser in situ keratomileusis using a wavefront-guided ablation profile: Refractive and visual outcomes.

Steven C Schallhorn1, Jan A Venter2, Stephen J Hannan2, Keith A Hettinger2, David Teenan2.   

Abstract

PURPOSE: To analyze results of wavefront-guided laser vision correction retreatments performed either by lifting the original flap or by surface ablation over the flap.
SETTING: Optical Express, Glasgow, United Kingdom.
DESIGN: Retrospective case series.
METHODS: This retrospective study included patients grouped according to whether they had flap lift enhancement or photorefractive keratectomy (PRK) performed over the LASIK flap. All retreatment procedures were performed with the Visx Star S4 IR excimer laser with wavefront-guided ablation profile derived from the iDesign aberrometer. Visual acuities, refractive outcomes, vector analysis of refractive cylinder and complications were analyzed in this study. The results of the last available clinical visit are presented.
RESULTS: This retrospective study included 290 eyes of 202 patients divided into 2 groups: 119 eyes that had flap lift enhancement (Group A), and 171 eyes in which photorefractive keratectomy (PRK) was performed over the LASIK flap (Group B). The mean follow-up was 4.0 ± 1.9 months in Group A and 4.2 ± 1.6 in Group B. The mean postoperative manifest spherical equivalent was -0.01 ± 0.35 D and +0.06 ± 0.39 D in Groups A and B, respectively. The percentage of eyes with postenhancement UDVA 20/20 or better was 87.4% in Group A and 79.5 % in Group B (P = .09). In Group A, 22 eyes (18.5%) developed epithelial ingrowth, of which surgical intervention was required in 2 eyes (1.7%). Grade 1 or less haze was noted in 9 (5.3%) eyes in Group B, and resolved in all cases within the first 6 postoperative months.
CONCLUSION: Both retreatment techniques were considered to be effective, predictable, and safe. FINANCIAL DISCLOSURE: Steven C Schallhorn MD is a consultant to Abbott Medical Optics and Zeiss, and Global Medical Director for Optical Express. None of the other authors have a financial or proprietary interest in the products and materials presented in this paper.
Copyright © 2015 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26703501     DOI: 10.1016/j.jcrs.2015.05.031

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  6 in total

1.  A Prospective Comparison of Wavefront-Guided LASIK versus Wavefront-Guided PRK After Previous Keratorefractive Surgery.

Authors:  Michele D Lee; Lisa Y Chen; Elaine M Tran; Edward E Manche
Journal:  Clin Ophthalmol       Date:  2020-10-20

Review 2.  Epithelial ingrowth following laser in situ keratomileusis (LASIK): prevalence, risk factors, management and visual outcomes.

Authors:  Darren Shu Jeng Ting; Sathish Srinivasan; Jean-Pierre Danjoux
Journal:  BMJ Open Ophthalmol       Date:  2018-03-29

3.  Femtosecond-Assisted Laser in situ Keratomileusis with de novo Flap Creation Following Previous Microkeratome Laser in situ Keratomileusis.

Authors:  Sloan W Rush; Ryan B Rush
Journal:  Clin Ophthalmol       Date:  2021-04-30

4.  Intraoperative optical coherence tomography-guided management of post-laser-assisted in situ keratomileusis epithelial ingrowth.

Authors:  Manpreet Kaur; Sridevi Nair; Saima A Mazumdar; Jeewan S Titiyal
Journal:  Indian J Ophthalmol       Date:  2022-01       Impact factor: 1.848

5.  Laser-Assisted In Situ Keratomileusis (LASIK) Enhancement for Residual Refractive Error after Primary LASIK.

Authors:  Majid Moshirfar; Noor F Basharat; Nour Bundogji; Emilie L Ungricht; Ines M Darquea; Matthew E Conley; Yasmyne C Ronquillo; Phillip C Hoopes
Journal:  J Clin Med       Date:  2022-08-18       Impact factor: 4.964

Review 6.  Complications of laser-assisted in situ keratomileusis.

Authors:  Pranita Sahay; Rahul Kumar Bafna; Jagadesh C Reddy; Rasik B Vajpayee; Namrata Sharma
Journal:  Indian J Ophthalmol       Date:  2021-07       Impact factor: 1.848

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.